Nivalis Therapeutics Company Profile (NASDAQ:NVLS)

About Nivalis Therapeutics

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVLS
  • CUSIP:
Key Metrics:
  • Previous Close: $2.62
  • 50 Day Moving Average: $2.29
  • 200 Day Moving Average: $4.93
  • 52-Week Range: $15,656,000.00 - $2.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.98
  • P/E Growth: 0.00
  • Market Cap: $41.18M
  • Outstanding Shares: 15,656,000
  • Beta: -0.36
Profitability:
  • Return on Equity: -41.72%
  • Return on Assets: -39.02%
Debt:
  • Current Ratio: 12.82%
  • Quick Ratio: 12.82%
Additional Links:
Companies Related to Nivalis Therapeutics:

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:NVLS) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.65 (266.92% upside)

Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:NVLS)
Show:
DateFirmActionRatingPrice TargetDetails
11/29/2016HC WainwrightReiterated RatingBuy$30.00 -> $6.00View Rating Details
11/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformView Rating Details
11/29/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
11/29/2016Robert W. BairdDowngradeOutperform -> Neutral$29.00 -> $3.00View Rating Details
11/29/2016Stifel NicolausDowngradeBuy -> Hold$16.00 -> $3.25View Rating Details
8/30/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Nivalis Therapeutics (NASDAQ:NVLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
2/13/2017Q4 16($0.55)($0.50)ViewN/AView Earnings Details
11/7/2016Q3($0.59)($0.48)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.42)($0.39)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nivalis Therapeutics (NASDAQ:NVLS)
Current Year EPS Consensus Estimate: $-1.68 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS

Dividends

Dividend History for Nivalis Therapeutics (NASDAQ:NVLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nivalis Therapeutics (NASDAQ:NVLS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 75.85%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.49View SEC Filing  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.00View SEC Filing  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.20View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nivalis Therapeutics (NASDAQ:NVLS)
DateHeadline
News IconNivalis Therapeutics Inc NVLS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:NVLS)
www.bioportfolio.com - February 17 at 4:36 PM
finance.yahoo.com logoNIVALIS THERAPEUTICS, INC. Financials (NASDAQ:NVLS)
finance.yahoo.com - February 17 at 4:36 PM
News IconImpact of Brokerage Rating on Nivalis Therapeutics, Inc.(NVLS) (NASDAQ:NVLS)
prensariotiretail.com - February 16 at 6:29 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Nivalis Therapeutics Inc (NASDAQ:NVLS)? - Winfield Review (NASDAQ:NVLS)
winfieldreview.com - February 16 at 6:29 PM
News IconInvestor Corner: Checking in on Shares of Nivalis Therapeutics Inc. (NVLS) - Baxter Review (NASDAQ:NVLS)
baxternewsreview.com - February 16 at 6:29 PM
News IconTrading Insight: Taking a Look at Levels for Nivalis Therapeutics Inc. (NVLS) - Rives Journal (NASDAQ:NVLS)
rivesjournal.com - February 15 at 3:08 AM
4-traders.com logoNivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Results of Operations and Financial Condition (NASDAQ:NVLS)
www.4-traders.com - February 14 at 10:08 PM
sg.finance.yahoo.com logoNivalis Therapeutics reports 4Q loss (NASDAQ:NVLS)
sg.finance.yahoo.com - February 14 at 10:08 PM
us.rd.yahoo.com logo4:14 pm Nivalis Therapeutics beats on Q4 EPS (NASDAQ:NVLS)
us.rd.yahoo.com - February 14 at 1:07 AM
News IconNivalis posts $31.5M loss for 2016; staff reduction continues (NASDAQ:NVLS)
bizwest.com - February 13 at 8:06 PM
4-traders.com logoNIVALIS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:NVLS)
www.4-traders.com - February 13 at 8:06 PM
rttnews.com logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q4 Earnings Report (NASDAQ:NVLS)
www.rttnews.com - February 13 at 8:06 PM
us.rd.yahoo.com logoNivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results (NASDAQ:NVLS)
us.rd.yahoo.com - February 13 at 8:06 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:NVLS)
biz.yahoo.com - February 13 at 8:06 PM
News IconTechnical Toolbox: Investor Focus on Nivalis Therapeutics Inc. (NVLS) - Piedmont Register (NASDAQ:NVLS)
piedmontregister.com - February 9 at 12:50 AM
News IconMy Watchlist for Thursday, February 09 (NASDAQ:NVLS)
ac-investor.blogspot.com - February 8 at 7:50 PM
News IconEndo International (NASDAQ:ENDP)- Stock Picks With Profit ... - Street Wise Report (press release) (blog) (NASDAQ:NVLS)
streetwisereport.com - February 6 at 7:01 PM
News IconChecking Indicator Levels for Nivalis Therapeutics Inc. (NVLS) - Sherwood Daily (NASDAQ:NVLS)
sherwooddaily.com - February 1 at 8:01 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Nivalis Therapeutics Inc (NASDAQ:NVLS)? - Wall Street Beacon (NASDAQ:NVLS)
wsbeacon.com - February 1 at 8:01 PM
News IconAnalysts Take the Wheel on Nivalis Therapeutics Inc (NASDAQ:NVLS) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:NVLS)
aikenadvocate.com - February 1 at 12:56 AM
News IconCalling all Bargain Hunters: Stock Update on Nivalis Therapeutics, Inc. (NASDAQ:NVLS) - Prospect Journal (NASDAQ:NVLS)
prospectjournal.com - February 1 at 12:56 AM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Nivalis Therapeutics Inc. (NVLS) - Sherwood Daily (NASDAQ:NVLS)
sherwooddaily.com - January 31 at 7:55 PM
News IconWatching Technical Levels on Shares of Nivalis Therapeutics Inc. (NVLS) - Sherwood Daily (NASDAQ:NVLS)
sherwooddaily.com - January 31 at 12:40 AM
News IconIs the Needle Ready to Move on Nivalis Therapeutics, Inc. (NASDAQ:NVLS) - Prospect Journal (NASDAQ:NVLS)
prospectjournal.com - January 31 at 12:40 AM
News IconEarnings in Full Force, Analysts Take Aim at Nivalis Therapeutics Inc (NASDAQ:NVLS) - Wall Street Beacon (NASDAQ:NVLS)
wsbeacon.com - January 29 at 12:04 AM
News IconAnalysts Sentiment on Nivalis Therapeutics, Inc. (NVLS) - Highland Mirror (NASDAQ:NVLS)
www.highlandmirror.com - January 29 at 12:04 AM
News IconMy Watchlist for Tuesday, January 24 (NASDAQ:NVLS)
ac-investor.blogspot.com - January 23 at 7:18 PM
News IconNivalis Therapeutics Inc NVLS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:NVLS)
www.bioportfolio.com - January 21 at 5:45 AM
insidermonkey.com logoHere’s What Happens Now At Nivalis Therapeutics Inc (NVLS) (NASDAQ:NVLS)
www.insidermonkey.com - January 16 at 7:27 PM
4-traders.com logoNivalis Therapeutics : Announces Corporate Restructuring (NASDAQ:NVLS)
www.4-traders.com - January 14 at 7:02 PM
bizjournals.com logoColorado biotech slashes staff, axes CEO (NASDAQ:NVLS)
www.bizjournals.com - January 13 at 11:40 PM
News IconNivalis cutting 25 jobs including CEO, chief medical officer (NASDAQ:NVLS)
bizwest.com - January 13 at 5:36 AM
4-traders.com logoNivalis Therapeutics : Boulder's Nivalis cuts 25 jobs, including CEO, as it contemplates a sale (NASDAQ:NVLS)
www.4-traders.com - January 13 at 12:34 AM
nasdaq.com logoNivalis Therapeutics To Eliminate 25 Jobs, Including CEO (NASDAQ:NVLS)
www.nasdaq.com - January 13 at 12:34 AM
streetinsider.com logoNivalis Therapeutics (NVLS) Approves Corporate Restructuring; CEO to Step Down (NASDAQ:NVLS)
www.streetinsider.com - January 13 at 12:34 AM
finance.yahoo.com logoNivalis Therapeutics Announces Corporate Restructuring (NASDAQ:NVLS)
finance.yahoo.com - January 12 at 7:33 PM
finance.yahoo.com logo4:12 pm Nivalis Therapeutics Board of Directors has approved a restructuring plan as part of the initiative to explore strategic alternatives; cutting 25 of 30 employees, including the CEO and CMO (NASDAQ:NVLS)
finance.yahoo.com - January 12 at 7:33 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors (NASDAQ:NVLS)
biz.yahoo.com - January 12 at 7:33 PM
marketwatch.com logoNivalis to lay off CEO and 80% of staff as part of restructuring (NASDAQ:NVLS)
www.marketwatch.com - January 12 at 7:33 PM
bizjournals.com logoTrump triggers Colorado biotech stock sell-off after targeting drug industry (Video) (NASDAQ:NVLS)
www.bizjournals.com - January 11 at 7:35 PM
baystreet.ca logoNivalis Therapeutics (NVLS) Gains on Alternatives Search (NASDAQ:NVLS)
www.baystreet.ca - January 7 at 12:41 AM
News IconMy Watchlist for Wednesday, January 04 (NASDAQ:NVLS)
ac-investor.blogspot.com - January 3 at 11:15 PM
benzinga.com logoNivalis Therapeutics Surrenders Early Gains (NASDAQ:NVLS)
www.benzinga.com - January 3 at 11:15 PM
News IconNivalis explores ‘strategic alternatives,’ including possible sale (NASDAQ:NVLS)
bizwest.com - January 3 at 11:15 PM
News IconBoulder's Nivalis exploring options, including a sale (NASDAQ:NVLS)
www.dailycamera.com - January 3 at 11:15 PM
streetinsider.com logoNivalis Therapeutics (NVLS) to Explore Strategic Options (NASDAQ:NVLS)
www.streetinsider.com - January 3 at 11:15 PM
publicnow.com logoNivalis Therapeutics Announces Review of Strategic Alternatives (NASDAQ:NVLS)
www.publicnow.com - January 3 at 11:15 PM
bizjournals.com logoColorado biotech to streamline operations, explore alternatives after clinical trial failure (NASDAQ:NVLS)
www.bizjournals.com - January 3 at 11:15 PM
News IconNASDAQ:NVLS Shareholder News: Investigation of Nivalis Therapeutics Inc announced (NASDAQ:NVLS)
www.groundreport.com - December 14 at 12:22 AM
sbwire.com logoNivalis Therapeutics Inc (NVLS) Investor Investigation over Possible Violations of Securities Laws (NASDAQ:NVLS)
www.sbwire.com - December 7 at 11:54 PM

Social

What is Nivalis Therapeutics' stock symbol?

Nivalis Therapeutics trades on the NASDAQ under the ticker symbol "NVLS."

Where is Nivalis Therapeutics' stock going? Where will Nivalis Therapeutics' stock price be in 2017?

6 brokers have issued 1 year target prices for Nivalis Therapeutics' shares. Their forecasts range from $3.00 to $20.00. On average, they expect Nivalis Therapeutics' stock price to reach $9.65 in the next twelve months.

When will Nivalis Therapeutics announce their earnings?

Nivalis Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Nivalis Therapeutics stock?

Here are some recent quotes from research analysts about Nivalis Therapeutics stock:

  • According to Zacks Investment Research, "Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. " (2/1/2017)

  • Cowen and Company analysts commented, "Nivalis reported a Q4 net loss of $6.6MM and ended 2015 with a cash balance of." (3/1/2016)

Who owns Nivalis Therapeutics stock?

Nivalis Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Deerfield Management Co. (24.01%), Kingdon Capital Management L.L.C. (3.34%) and Perceptive Advisors LLC (0.79%). Company insiders that own Nivalis Therapeutics stock include Bay Master Investors (C Hawkes, David Malcom Rodman, Global Healthcare Mas Jennison, James E Flynn, Jon Congleton, R Michael Carruthers and Robert E Conway.

Who sold Nivalis Therapeutics stock? Who is selling Nivalis Therapeutics stock?

Nivalis Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C..

Who bought Nivalis Therapeutics stock? Who is buying Nivalis Therapeutics stock?

Nivalis Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Nivalis Therapeutics stock in the last two years include Bay Master Investors (C Hawkes, Global Healthcare Mas Jennison, James E Flynn, Jon Congleton, R Michael Carruthers and Robert E Conway.

How do I buy Nivalis Therapeutics stock?

Shares of Nivalis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nivalis Therapeutics stock cost?

One share of Nivalis Therapeutics stock can currently be purchased for approximately $2.63.

Nivalis Therapeutics (NASDAQ:NVLS) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)

Earnings History Chart

Earnings by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)

Dividend History Chart

Dividend Payments by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)

Last Updated on 2/19/2017 by MarketBeat.com Staff